首页> 外文期刊>Pediatric clinics of North America >Therapies and vaccines for emerging bacterial infections: learning from methicillin-resistant Staphylococcus aureus.
【24h】

Therapies and vaccines for emerging bacterial infections: learning from methicillin-resistant Staphylococcus aureus.

机译:新兴细菌感染的疗法和疫苗:向耐甲氧西林的金黄色葡萄球菌学习。

获取原文
获取原文并翻译 | 示例
       

摘要

Methicillin-resistant Staphylococcus aureus (MRSA) is an emerging bacterial infection worldwide, and community-acquired MRSA (CA-MRSA) infection, which has increased dramatically in frequency in many areas, is of particular clinical and public health concern. CA-MRSA outbreaks and severe infections have been reported more frequently in children, often manifesting in one of two distinct clinical syndromes, furunculosis or necrotizing pneumonia. This article outlines the molecular biology of MRSA, how molecular biology has contributed to the understanding of MRSA infections, current therapy and prevention of MRSA, and the prospects for a vaccine against S aureus.
机译:耐甲氧西林的金黄色葡萄球菌(MRSA)是世界范围内一种新兴的细菌感染,在许多领域,社区获得性MRSA(CA-MRSA)感染的发生率显着增加,这特别引起临床和公共卫生关注。在儿童中,CA-MRSA暴发和严重感染的报道更为频繁,通常表现为两种不同的临床综合征之一:糠fur病或坏死性肺炎。本文概述了MRSA的分子生物学,分子生物学如何促进对MRSA感染的了解,MRSA的当前治疗和预防以及抗金黄色葡萄球菌疫苗的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号